N-[(2S,4R)-4-benzyl-2-hydroxy-5-[4-(hydroxymethyl)piperidin-1-yl]-5-oxopentyl]-4-nitrobenzenesulfonamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-[(2S,4R)-4-benzyl-2-hydroxy-5-[4-(hydroxymethyl)piperidin-1-yl]-5-oxopentyl]-4-nitrobenzenesulfonamide
• 化学式: C24H31N3O7S
• 分子量: 505.6
• InChiKey: CBHBZQGVJBBUBS-IRLDBZIGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  35
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  161
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
  申请人：CERULEAN PHARMA INC.

  公开号：US20130196945A1

  公开（公告）日：2013-08-01

  The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.

  本发明涉及一种新型治疗环糊精含聚合物组成物，其设计为小分子治疗药物传递的载体以及其制药组合物。这些含环糊精聚合物可提高药物稳定性和溶解度，并在体内使用时减少小分子治疗药物的毒性。此外，通过从各种连接基团和靶向配体中进行选择，这些聚合物提供了治疗剂的控制释放方法。本发明还涉及使用所述治疗组成物治疗受试者的方法。本发明还涉及用于进行制药业务的方法，包括制造、许可或分发包含或涉及所述聚合物化合物的工具包。
• INHIBITORS OF CENTRAL NERVOUS SYSTEM VASOACTIVE INHIBITORY PEPTIDE RECEPTOR 2
  申请人：The Trustees Of Columbia University In The City Of New York

  公开号：US20150239831A1

  公开（公告）日：2015-08-27

  The present invention relates to compounds that inhibit VIPR 2 in the CNS, pharmaceutical compositions comprising said compounds, and methods of using such compounds and compositions in the treatment of a CNS disorder such as a behavioral disorder, including but not limited to schizophrenia.
• [EN] INHIBITORS OF CENTRAL NERVOUS SYSTEM VASOACTIVE INHIBITORY PEPTIDE RECEPTOR 2<br/>[FR] INHIBITEURS DU RÉCEPTEUR 2 DE PEPTIDE INHIBITEUR VASO-ACTIF DU SYSTÈME NERVEUX CENTRAL
  申请人：UNIV COLUMBIA

  公开号：WO2014075096A1

  公开（公告）日：2014-05-15

  The present invention relates to compounds that inhibit VIPR2 in the CNS, pharmaceutical compositions comprising said compounds, and methods of using such compounds and compositions in the treatment of a CNS disorder such as a behavioral disorder, including but not limited to schizophrenia.